Oncoliq is an Argentinian startup based in Buenos Aires that combines cutting-edge AI with molecular biology to develop an early cancer detection screening method using a liquid biopsy blood test.
Subscribe to see Oncoliq’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Oncoliq is a healthcare company headquartered in Argentina. Its most recent funding round, Seed, raised $2.8M in July 2026. Xcout tracks 4 named people at Oncoliq, including Adriana de Siervi (founder).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $2.8M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Oncoliq's closest competitors — see the full list of competitors and alternatives →
Aitiologic is a precision-medicine startup based in Vienna that develops liquid biopsy platforms, including the aitios platform and aitios NIPPT. The company focuses on advanced molecular diagnostics to support personalized healthcare.
EarlyDiagnostics, also known as EarlyDx, is a clinical-stage precision diagnostics company that develops non-invasive liquid biopsy technologies and genomics platforms for early cancer detection.
Innocras is a genomic analysis and cancer big data company founded in South Korea by physician-scientists from KAIST, maintaining research and corporate presence in both the United States and Korea. The company specializes in advanced cancer diagnostics and genomic technology to support precision oncology.
AOA Dx Inc. is a US-based diagnostics biotechnology company with offices in Boston, New York, and London, focusing on the early detection of ovarian cancer.
Tempus AI, Inc. is an American health technology company founded in 2015 in Chicago, Illinois. The company builds a practical platform to gather and analyze clinical and molecular data, empowering physicians to make data-driven patient care decisions.
A3P Biomedical is a Swedish private diagnostics company that specializes in advanced prostate cancer screening. Its lead product, Stockholm3, combines protein markers, genetic markers, and clinical data using an advanced algorithm to detect aggressive prostate cancer.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Oncoliq? Suggest a correction · Work at Oncoliq? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.